Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15577018 | 0.84 | RXRA (0.35) | PTGS2 | |
| SCHEMBL10192324 | 0.79 | MMP1 (0.32) | NPC1RAB9APTGS2MAPTADAMTS4 | |
| SCHEMBL10246532 | 0.79 | TSHR (0.52) | TSHR | |
| SCHEMBL11840980 | 0.75 | PTGS2 (0.39) | PTGS2FFAR1MAPTADAMTS4CYP1A2 | |
| SCHEMBL11840724 | 0.74 | PTGS2 (0.38) | TSHRPTGS2FFAR1MAPTADAMTS4 | |
| SCHEMBL28186860 | 0.71 | — | — | |
| SCHEMBL11841177 | 0.70 | MGLL (0.41) | NPC1RAB9APPARA | |
| SCHEMBL19705372 | 0.67 | TSHR (0.50) | TSHR | |
| SCHEMBL3628638 | 0.67 | GRIA4 (0.51) | TSHRPTGS2CYP17A1 | |
| SCHEMBL16687011 | 0.67 | GRIA4 (0.51) | TSHRPTGS2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | TSHR 4051/4885NPC1 815/4885RAB9A 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.